FibroGen, Inc. (FGEN)

1,1600 -0,0600 (-4,92%) Börsenschluss: 04:00PM EDT

FibroGen, Inc.

409 Illinois Street
San Francisco, CA 94158
United States
415 978 1200
https://www.fibrogen.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 486

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Thane Wettig	CEO & Director	941,79k	N/A	1965
Mr. Juan Graham	Senior VP & CFO	892,49k	N/A	1977
Ms. Christine L. Chung	Senior Vice President of China Operations	915,36k	N/A	1968
Dr. Barry A. Berkowitz Ph.D.	Founder	N/A	N/A	N/A
Dr. John J. Hunter Ph.D.	Chief Scientific Officer	N/A	N/A	1963
David DeLucia	Vice President of Corporate FP&A and Investor Relations	N/A	N/A	N/A
Mr. Michael D. Lowenstein J.D., Ph.D.	Chief Legal Officer	N/A	N/A	N/A
Ms. Tricia Stewart	Chief People Officer	N/A	N/A	N/A
Mr. Kirk A. Christoffersen MBA	Chief Business Officer	N/A	N/A	1969
Dr. Rahul Rajan Kaushik Ph.D.	Senior Vice President of Pharmaceutical Development, Technical Operations & Manufacturing	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Corporate Governance

FibroGen, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 8. Die grundlegenden Scores sind Audit: 10, Vorstand: 2, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.